OBJECTIVES: Antimicrobial resistance patterns change over time and longitudinal surveillance studies provide insight into these trends. We sought to describe the important trends in antimicrobial resistance in key pathogens across Canada to provide useful information to clinicians, policy makers and industry, to assist in optimizing antimicrobial therapy, formulary choices and drug development. METHODS: We analysed longitudinal data from the CANWARD study using a multivariate regression model to control for possible effects of patient demographics on resistance, in order to assess the impact of time on antimicrobial resistance independent of other measured variables. RESULTS: We identified several key trends in common pathogens. In particular, we observed a statistically significant increase in the proportion of Escherichia coli isolates that were resistant to extended-spectrum cephalosporins and fluoroquinolones, an increase in the proportion of Klebsiella pneumoniae isolates that were resistant to extended-spectrum cephalosporins, a reduction in the proportion of Staphylococcus aureus that were methicillin, clindamycin and trimethoprim/sulfamethoxazole resistant, and a reduction in the proportion of Pseudomonas aeruginosa that were fluoroquinolone and gentamicin resistant. CONCLUSIONS: Although some of these trends, such as the dramatic increase in fluoroquinolone and cephalosporin resistance in E. coli, can be attributed to the emergence and global spread of resistant clones (e.g. ST131 E. coli), others remain unexplained. However, recognizing these trends remains important to guide changes in empirical antimicrobial therapy and drug development.
OBJECTIVES: Antimicrobial resistance patterns change over time and longitudinal surveillance studies provide insight into these trends. We sought to describe the important trends in antimicrobial resistance in key pathogens across Canada to provide useful information to clinicians, policy makers and industry, to assist in optimizing antimicrobial therapy, formulary choices and drug development. METHODS: We analysed longitudinal data from the CANWARD study using a multivariate regression model to control for possible effects of patient demographics on resistance, in order to assess the impact of time on antimicrobial resistance independent of other measured variables. RESULTS: We identified several key trends in common pathogens. In particular, we observed a statistically significant increase in the proportion of Escherichia coli isolates that were resistant to extended-spectrum cephalosporins and fluoroquinolones, an increase in the proportion of Klebsiella pneumoniae isolates that were resistant to extended-spectrum cephalosporins, a reduction in the proportion of Staphylococcus aureus that were methicillin, clindamycin and trimethoprim/sulfamethoxazole resistant, and a reduction in the proportion of Pseudomonas aeruginosa that were fluoroquinolone and gentamicin resistant. CONCLUSIONS: Although some of these trends, such as the dramatic increase in fluoroquinolone and cephalosporin resistance in E. coli, can be attributed to the emergence and global spread of resistant clones (e.g. ST131E. coli), others remain unexplained. However, recognizing these trends remains important to guide changes in empirical antimicrobial therapy and drug development.
Authors: Rachel D Savage; Robert A Fowler; Asgar H Rishu; Sean M Bagshaw; Deborah Cook; Peter Dodek; Richard Hall; Anand Kumar; François Lamontagne; François Lauzier; John Marshall; Claudio M Martin; Lauralyn McIntyre; John Muscedere; Steven Reynolds; Henry T Stelfox; Nick Daneman Journal: CMAJ Open Date: 2016-10-13
Authors: C Slekovec; J Robert; D Trystram; J M Delarbre; A Merens; N van der Mee-Marquet; C de Gialluly; Y Costa; J Caillon; D Hocquet; X Bertrand Journal: Eur J Clin Microbiol Infect Dis Date: 2014-05-07 Impact factor: 3.267
Authors: James R Johnson; Paul Thuras; Brian D Johnston; Scott J Weissman; Ajit P Limaye; Kim Riddell; Delia Scholes; Veronika Tchesnokova; Evgeni Sokurenko Journal: Clin Infect Dis Date: 2016-03-29 Impact factor: 9.079
Authors: N M Olarte Escobar; I A Valderrama Márquez; J Avila Quiroga; T Goretty Trujillo; F González; M I Garzón Aguilar; J Escobar-Pérez Journal: Epidemiol Infect Date: 2017-01-09 Impact factor: 4.434
Authors: Harvey N Summerlin; Cícero C Pola; Eric S McLamore; Terry Gentry; Raghupathy Karthikeyan; Carmen L Gomes Journal: Front Microbiol Date: 2021-05-20 Impact factor: 5.640